Calithera Biosciences, Inc.
DelistedCIK 1496671fmd_19405BMD5ZSFFSD0D1CMA32X2CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Dec 31, 2022, 39 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 26 | 22 | – | – | 10 | – |
| Net interest income | 0 | 0 | 0 | 0 | 2 | 3 | – | – | – | – |
| Research and development | 10 | 16 | 24 | 28 | 43 | 66 | 76 | 71 | 53 | 29 |
| Total operating expenses | 12 | 22 | 33 | 38 | 56 | 80 | 93 | 91 | 125 | 42 |
| Operating income | (12) | (22) | (33) | (38) | (30) | (57) | (93) | (91) | (115) | (42) |
| Interest and investment income | – | – | – | – | 2 | 3 | 3 | 1 | 0 | 0 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | 1 | 0 | 2 |
| Income before taxes | – | – | (33) | (38) | (28) | (55) | (90) | (90) | (115) | (40) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (33) | (38) | (28) | (55) | (90) | (90) | (115) | (40) |
| Net income | (12) | (22) | (33) | (38) | (28) | (55) | (90) | (90) | (115) | (40) |
| Net income to common shareholders | (12) | (22) | – | – | – | – | – | (90) | (115) | (21) |